Metabolic Syndrome

Metabolic Syndrome - Defining the Danger

Prothrombotic, proinflammatory state. Diagnosis: ≥3 of 5 criteria (📌).

⭐ NCEP ATP III criteria are widely used for diagnosing Metabolic Syndrome, requiring at least three out of five specific risk factors.

Pathophysiology - Insulin's Resistance Riot

• Core Defect: Insulin Resistance (IR) - liver, muscle, adipose cells resist insulin action.
• Primary Drivers of IR:
  • Visceral Adiposity: Central fat.
    • Alters adipokine secretion:
      • ↓ Adiponectin (sensitizing).
      • ↑ TNF-α, ↑ Resistin (pro-IR).
  • Chronic Inflammation & Oxidative Stress.
  • Genetics & Lifestyle (diet, inactivity).

⭐ Insulin resistance, often driven by visceral adiposity and altered adipokine secretion (e.g., ↓adiponectin, ↑TNF-α, ↑resistin), is the central pathophysiological mechanism in Metabolic Syndrome.

• Consequences (The "Riot"):
  • Hyperinsulinemia: Compensatory; β-cell failure risk.
  • Hyperglycemia: ↓Muscle uptake, ↑hepatic output.
  • Atherogenic Dyslipidemia: ↑TGs, ↓HDL-C, ↑small dense LDL (sdLDL).
  • Hypertension: Endothelial dysfunction, ↑SNS, ↑RAAS.
  • Pro-inflammatory/thrombotic state.

Clinical Impact - The Body's Alarms

⭐ Metabolic Syndrome significantly elevates the risk of developing Type 2 Diabetes Mellitus (up to 5-fold) and atherosclerotic Cardiovascular Disease (up to 2-fold).

• Systemic Consequences & Associated Conditions:
  • Endocrine:
    • Type 2 Diabetes Mellitus (T2DM): Due to insulin resistance.
    • Polycystic Ovary Syndrome (PCOS) in women.
  • Cardiovascular:
    • Atherosclerotic CVD (ASCVD): Myocardial Infarction (MI), Stroke, Peripheral Artery Disease.
    • Hypertension: Often a core component.
  • Hepatic:
    • Non-alcoholic Fatty Liver Disease (NAFLD), progressing to Non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis.
  • Renal:
    • Chronic Kidney Disease (CKD), microalbuminuria.
  • Respiratory:
    • Obstructive Sleep Apnea (OSA).
  • Musculoskeletal:
    • Gout (Hyperuricemia).
  • Oncologic:
    • ↑ Risk of certain cancers (e.g., colorectal, breast, endometrial).
• Overall Impact: ↑ All-cause mortality, ↓ Quality of life.

Management - Reversing the Risks

⭐ Lifestyle modification, including dietary changes (e.g., DASH or Mediterranean diet), increased physical activity (≥150 min/week moderate intensity), and weight reduction, is the cornerstone of Metabolic Syndrome management.

Management is comprehensive, targeting risk factor reduction. 📌 Mnemonic: ABCDE (Assess risk/Aspirin, Blood pressure, Cholesterol/Cigarettes, Diet/Diabetes, Exercise).

• Core Strategy: Aggressive lifestyle changes are paramount.
• Pharmacological Aid: Medications address individual components if lifestyle targets are not met.
  • Prioritize agents with benefits beyond single risk factors (e.g., ACEi/ARBs in diabetes).
• Surgical Option: Bariatric surgery for refractory severe obesity.
• Monitoring: Regular follow-up to assess efficacy and adjust therapy.

High‑Yield Points - ⚡ Biggest Takeaways

• Metabolic Syndrome: Cluster of ≥3 risk factors: central obesity, ↑ triglycerides (≥150 mg/dL), ↓ HDL-C (<40M/<50F mg/dL), ↑ BP (≥130/85 mmHg), ↑ fasting glucose (≥100 mg/dL).
• Insulin resistance is the core mechanism.
• Diagnosis by NCEP ATP III criteria (3 of 5).
• Significantly ↑ risk for CVD, Type 2 DM, and NAFLD.
• Altered adipokines (e.g., ↓ adiponectin, ↑ TNF-α) contribute.
• Lifestyle modification (diet, exercise) is primary treatment.